Pathway Capital Management LP Has $4.17 Million Stock Holdings in GoodRx Holdings, Inc. $GDRX

Pathway Capital Management LP increased its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 69.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 986,158 shares of the company’s stock after acquiring an additional 402,721 shares during the quarter. GoodRx makes up about 20.5% of Pathway Capital Management LP’s portfolio, making the stock its 3rd largest position. Pathway Capital Management LP’s holdings in GoodRx were worth $4,171,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of GDRX. Ameriprise Financial Inc. lifted its position in GoodRx by 4.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 4,819,505 shares of the company’s stock valued at $24,001,000 after acquiring an additional 184,734 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in GoodRx by 16.5% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,671,521 shares of the company’s stock valued at $8,324,000 after acquiring an additional 236,896 shares during the last quarter. Pacer Advisors Inc. bought a new position in GoodRx during the third quarter valued at $3,687,000. Goldman Sachs Group Inc. grew its stake in shares of GoodRx by 7.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 783,378 shares of the company’s stock worth $3,455,000 after acquiring an additional 54,783 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of GoodRx in the third quarter worth about $3,036,000. 63.77% of the stock is owned by institutional investors and hedge funds.

GoodRx Price Performance

Shares of NASDAQ:GDRX opened at $2.28 on Tuesday. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.81. The stock has a market cap of $773.91 million, a PE ratio of 25.33, a PEG ratio of 0.86 and a beta of 1.45. The company’s fifty day moving average is $2.70 and its 200 day moving average is $3.55. GoodRx Holdings, Inc. has a 52 week low of $2.24 and a 52 week high of $5.81.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The company had revenue of $196.03 million for the quarter, compared to the consensus estimate of $195.17 million. GoodRx had a net margin of 3.97% and a return on equity of 9.73%. The firm’s quarterly revenue was up .4% compared to the same quarter last year. During the same period last year, the business posted $0.08 earnings per share. Research analysts anticipate that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

Analyst Ratings Changes

GDRX has been the topic of a number of analyst reports. TD Cowen decreased their price objective on GoodRx from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Monday, November 10th. Morgan Stanley lowered their target price on shares of GoodRx from $5.00 to $4.00 and set an “equal weight” rating on the stock in a research note on Thursday, December 18th. JPMorgan Chase & Co. decreased their price target on shares of GoodRx from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Citigroup dropped their price objective on shares of GoodRx from $5.00 to $4.50 and set a “buy” rating for the company in a report on Friday, January 9th. Finally, Barclays started coverage on shares of GoodRx in a research report on Monday, December 8th. They issued an “underweight” rating and a $3.00 target price for the company. Five analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $4.73.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.